Fin|Tech|Bio at Canary Wharf

Join Level39 and Canary Wharf Group Life Sciences for the first Fin|Tech|Bio at Canary Wharf event of 2025.

This event series brings together innovators, investors, and industry stakeholders at the intersection of finance, technology, and biotech. Expect thought-provoking discussions, meaningful connections, and an opportunity to contribute to the development of the Canary Wharf ecosystem.

Fin|Tech|Bio at Canary Wharf Details

• Date: Tuesday 25th March 2025
• Time: 6:00 PM – 8:00 PM
• Organiser: Level39 & Canary Wharf Life Sciences
• Venue: Space39, Level39, Canary Wharf

About the Speakers

Leigh Brody – Investment Manager, AlbionVC

Leigh Brody specialises in transformative technologies and therapeutics within life sciences. She joined AlbionVC in 2021 after leading a spin-out based on her own novel technology and contributing to companies such as Desktop Genetics and Quell Therapeutics.

With a background as both an academic and founder, Leigh brings deep expertise in identifying and supporting innovators in life sciences. She holds a PhD from Imperial College London and a BSc in Biochemistry from Simmons University. She has been recognised among the 50 Movers & Shakers in BioBusiness and 35 Under 35: Tech Entrepreneurs.

Sutha Satkunarajah – Senior Director of Programs, Flagship Pioneering UK

Sutha Satkunarajah leads efforts to develop and scale new companies focused on preempting, predicting, preventing, and delaying novel pathogens and chronic diseases.

Previously, he played a key role in one of the UK’s largest COVID-19 surveillance programs and has driven transformation initiatives across NHS organisations. Sutha holds a BA in Cognitive Science from Harvard College and was an Innovation Fellow at Imperial College’s Institute of Global Health Innovation.

Meri Beckwith – Co-Founder, LindusHealth

Meri Beckwith is the Co-Founder of LindusHealth, a company focused on improving clinical trials through better patient experience. Previously a venture capital investor and partner to biotech and digital health companies, Meri participated in COVID-19 vaccine trials as a volunteer. This experience highlighted the need for patient-centric approaches in trial design, shaping his vision for LindusHealth.

Muna Yusuf – Vice President of Ecosystem & Operations, Sanius Health

Muna Yusuf drives innovation in patient care, health systems, and pharmaceutical data solutions at Sanius Health. The company leverages AI, wearable, genomic, and outcomes data to empower patients and improve healthcare outcomes.

Sanius Health collaborates with 65 NHS trusts, reducing costs and enhancing patient monitoring through digital and personalised medicine. Muna plays a key role in accelerating research and ensuring pharma companies have access to a rich, patient-driven data ecosystem.

About the Chair/Moderator

Rowan Gardner – Co-founder and Chief Business & Investment Officer, PrecisionLife

Rowan Gardner has over 30 years of experience in computational life sciences, leveraging patient data to drive precision medicine. As Co-founder and Chief Business & Investment Officer at PrecisionLife, she focuses on advancing treatments for chronic diseases.

She also sits on the board of Digital Health and Care Wales, overseeing digital transformation within the NHS. Rowan holds a Master’s in Biochemistry from the University of Oxford and was part of one of its first spinouts, Oxford Molecular Group, later collaborating with CERN on cloud computing applications for healthcare.

About Fin|Tech|Bio at Canary Wharf

The Fin|Tech|Bio at Canary Wharf event is designed for professionals and innovators operating at the intersection of fintech, biotech, and technology. Attendees can expect insightful discussions, networking opportunities, and insights into the evolving landscape of TechBio and fintech collaborations.

Key Takeaways from Fin|Tech|Bio at Canary Wharf

• Industry trends: A look at 2024 reflections and what’s coming in 2025 for TechBio and fintech.
• Opportunities: How fintech can support innovation and growth in biotech.
• Insights from experts: Gain knowledge from investors, operators, and thought leaders in the industry.

Agenda

• 18:00: Guest arrival, registration, and networking
• 18:20: Welcome from Level39 and Canary Wharf Group
• 18:30: Panel discussion – 2024 reflections, 2025 TechBio trends, and opportunities for fintech
• 19:10: Audience Q&A
• 19:20: Networking with drinks & nibbles
• 20:00: Event close

About Level39

Level39 is a melting pot of innovators, investors, industry experts and ambitious entrepreneurs, pioneering change across the sectors that dictate our experiences in daily life – FinTech, Cyber Security, Data & AI,GreenTech, Life Sciences and more.

Our flexible co-working, private office space and ecosystem activities provide members with access to the environment and growth opportunities they need to develop into world-leading businesses, that have a major financial and social impact.

To find out more, or arrange a time to meet the team, contact us at members@level39.co

About Canary Wharf Group Life Sciences

Canary Wharf Group is the developer of the largest urban regeneration project in Europe. We develop, manage and own interests in approximately 8 million sq ft of office space, 1.1 million sq ft of retail and over 2,200 apartments.

Canary Wharf aspires to become a globally recognised life science ecosystem in East London. We have 100k sqft of occupied CL2/CL3 laboratory and office space and over 40 life science and healthcare companies across the estate. We will be adding a further 50k sqft of labortory and office facilities this year before opening One North Quay, Europe’s largest and most technically advanced commercial life science building, in Q4 2027 with Kadans Science Partner.